- Home
- MIST vs CNTB Comparison
MIST vs CNTB Comparison
Compare MIST & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 135.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | CNTB |
|---|---|---|
| Price | $1.03 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.00 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.7M | 356.6K |
| Earning Date | 05-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $1.23 |
| 52 Week High | $3.06 | $3.82 |
Technical Indicators
Market Signals| Indicator | MIST | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 49.81 |
| Support Level | $1.01 | $2.01 |
| Resistance Level | $1.42 | $2.69 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 5.56 | 39.08 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.